NGNE — Neurogene Income Statement
0.000.00%
Last trade - 00:00
- $472.35m
- $302.92m
- 29
- 29
- 81
- 43
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 71 | 33.7 | 60.7 | 59.1 | 39.2 |
Operating Profit | -71 | -33.7 | -60.7 | -59.1 | -39.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -69.4 | -33.3 | -60.7 | -57.6 | -36.3 |
Net Income After Taxes | -69.4 | -33.3 | -60.7 | -57.6 | -36.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -69.4 | -33.3 | -60.7 | -57.6 | -36.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -69.4 | -33.3 | -60.7 | -57.6 | -36.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -84.8 | -79.3 | -110 | -104 | -4.11 |